Nd Substantially Enhances Their Safety The Project Is Now Entering Final Process Validation Phase Of Medium Fill Procedures New Offering Reinforces Amaran Biotech 39s Recognition Asa Leading Cdmo Contract Development Amp Manufacturing Organization With Many Years Extensive Experience In Processes High Value Biopharmaceuticals News Today : Breaking News, Live Updates & Top Stories | Vimarsana
HSINCHU, July 13, 2022 /PRNewswire/ Amaran Biotechnology Inc., a subsidiary of Taiwan's OBI Pharma Inc., today announced that the construction of its fully-automated aseptic filling line and facilities, a first in Taiwan, has been completed. The new facility minimizes the risks of human factors affecting the quality of the pharmaceutical products, and substantially enhances their safety. The project is now entering the final process validation phase of the medium fill procedures. The new offering reinforces Amaran Biotech's recognition as a leading CDMO (contract development & manufacturing organization) with many years of extensive experience in the development of manufacturing processes of high-value biopharmaceuticals, analysis services, and premium solutions for cGMP production. It also strengthens its position as the OEM of active pharmaceutical ingredients (APIs) of OBI Pharma's active immune-oncologic therapeutic products. Amaran Biotech's Quality Managemen